PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25558587-0	2014	[Successful treatment of epilepsy and circadian rhythm disturbance with levetiracetam in a patient with dentatorubral-pallidoluysian atrophy (DRPLA)].	Levetiracetam	72-85	atrophin 1	Homo sapiens	142-147	
25558587-1	2014	We report a 21-year-old male patient with dentatorubral-pallidoluysian atrophy (DRPLA) showing progressive myoclonus epilepsy (PME), who responded to levetiracetam (LEV) at an initial dose of 1,000 mg/day.	Levetiracetam	150-163	atrophin 1	Homo sapiens	80-85	
25558587-1	2014	We report a 21-year-old male patient with dentatorubral-pallidoluysian atrophy (DRPLA) showing progressive myoclonus epilepsy (PME), who responded to levetiracetam (LEV) at an initial dose of 1,000 mg/day.	Levetiracetam	165-168	atrophin 1	Homo sapiens	80-85	
25558587-6	2014	It is suggested that LEV may improve quality of life in patients with DRPLA, in addition to reducing the frequency of epileptic seizures.	Levetiracetam	21-24	atrophin 1	Homo sapiens	70-75	
21889282-0	2012	Amelioration of disabling myoclonus in a case of DRPLA by levetiracetam.	Levetiracetam	58-71	atrophin 1	Homo sapiens	49-54	
21889282-1	2012	We report on an 18-year-old male patient with dentatorubral-pallidoluysian atrophy (DRPLA) (number of CAG repeats: 68) with progressive myoclonus epilepsy (PME), who showed a dramatic response to levetiracetam in terms of the intensity of myoclonus.	Levetiracetam	196-209	atrophin 1	Homo sapiens	84-89	
21889282-9	2012	Reports on the efficacy of levetiracetam for myoclonus in DRPLA are still rare, though its effect on PME is known in the context of other neurological disorders.	Levetiracetam	27-40	atrophin 1	Homo sapiens	58-63	
21889282-10	2012	Thus levetiracetam should be subjected to clinical trials as a means of disabling myoclonus in DRPLA.	Levetiracetam	5-18	atrophin 1	Homo sapiens	95-100